Agenus, a biotech company focused on immuno-oncology, is launching a $100 million fundraising effort via a new security token, the Biotech Electronic Security Token (BEST). Agenus is the first healthcare firm to use security tokens. BEST is purposed for singular investments in biotech products., in this case the AGEN2034, an anti-body project for cancer research. BEST funnels capital to the product's development while sharing its future revenue streams with investors.